The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Open accessAbstract
BACKGROUND: Calcitonin gene-related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks. METHODS: In an international, multicenter, double-blind, randomized clinical trial of BIBN 4096 BS, a highly specific and potent nonpeptide CGRP-receptor antagonist, 126 patients with migraine received one of the following: placebo or 0.25, 0.5, 1, 2.5, 5, or 10 mg of BIBN 4096 BS intravenously over a period of 10 minutes. A group-sequential adaptive treatment-assignment design was used to minimize the number of patients exposed. RESULTS: The 2.5-mg dose was selected, with a response rate of 66 percent, as compared with 27 percent for placebo (P=0.001). The BIBN 4096 BS group as a whole had a response rate of 60 percent. Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief. An effect was apparent after 30 minutes and increased over the next few hours. The overall rate of adverse events was 25 percent after the 2.5-mg dose of the drug and 20 percent for the BIBN 4096 BS group as a whole, as compared with 12 percent for placebo. The most frequent side effect was paresthesia. There were no serious adverse events. CONCLUSIONS: The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goadsby, P. J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2004.00711.x · Cited by 2,381
Self-citationPrevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Migraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
Self-citationVasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Self-citationIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,336
Goadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Self-citationThe Global Burden of Disease Study: Implications for Neurology
Menken, M., Munsat, T. L., & Toole, J. F. (2000) · Archives of Neurology · doi:10.1001/archneur.57.3.418 · Cited by 1,058
Cgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P., Jacobsen, V., Iversen, H., Sperling, B., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,027
Self-citationFerrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Self-citation
Cited by
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Self-citationCalcitonin Gene-Related Peptide: Physiology and Pathophysiology
Russell, F. A., King, R., Smillie, S.-J., Kodji, X., & Brain, S. D. (2014) · Physiological Reviews · doi:10.1152/physrev.00034.2013 · Cited by 1,258
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705848 · Cited by 928
Self-citationPietrobon, D., & Moskowitz, M. A. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183717 · Cited by 680
Migraine and the trigeminovascular system—40 years and counting
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30185-1 · Cited by 606
Iyengar, S., Ossipov, M. H., & Johnson, K. W. (2017) · Pain · doi:10.1097/j.pain.0000000000000831 · Cited by 584
Origin of pain in migraine: evidence for peripheral sensitisation
Olesen, J., Burstein, R., Ashina, M., & Tfelt-Hansen, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70090-0 · Cited by 564
Self-citationDodick, D. W. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30478-1 · Cited by 557
Diencephalic and brainstem mechanisms in migraine
Akerman, S., Holland, P. R., & Goadsby, P. J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3057 · Cited by 532
Self-citationHo, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61626-8 · Cited by 531
CGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 523
Self-citationFerrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Self-citationCGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
Hansen, J. M., Hauge, A. W., Olesen, J., & Ashina, M. (2010) · Cephalalgia · doi:10.1177/0333102410368444 · Cited by 483
Self-citationInterictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
Cernuda-Morollón, E., Larrosa, D., Ramón, C., Vega, J., Martínez-Camblor, P., & Pascual, J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cb72 · Cited by 468
Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., & Rapoport, A. M. (2008) · Neurology · doi:10.1212/01.wnl.0000286940.29755.61 · Cited by 464
Croop, R., Goadsby, P. J., Stock, D. A., Conway, C. M., Forshaw, M., Stock, E. G., Coric, V., & Lipton, R. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31606-x · Cited by 403
Self-citationQin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 396
Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine
Russo, A. F. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124701 · Cited by 389
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors
Hoare, S. R. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03370-2 · Cited by 379
Dodick, D. W., Goadsby, P. J., Silberstein, S. D., Lipton, R. B., Olesen, J., Ashina, M., Wilks, K., Kudrow, D., Kroll, R., Kohrman, B., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70209-1 · Cited by 372
Self-citationGoadsby, P. J., Charbit, A. R., Andreou, A. P., Akerman, S., & Holland, P. R. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.03.019 · Cited by 371
Self-citationDodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Self-citationGuidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Self-citationSun, H., Dodick, D. W., Silberstein, S., Goadsby, P. J., Reuter, U., Ashina, M., Saper, J., Cady, R., Chon, Y., Dietrich, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00019-3 · Cited by 358
Self-citationUbrogepant for the Treatment of Migraine
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813049 · Cited by 349
Eftekhari, S., Salvatore, C. A., Calamari, A., Kane, S. A., Tajti, J., & Edvinsson, L. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.016 · Cited by 329
Lennerz, J. K., Rühle, V., Ceppa, E. P., Neuhuber, W. L., Bunnett, N. W., Grady, E. F., & Messlinger, K. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21607 · Cited by 325
Migraine as an inflammatory disorder
Waeber, C., & Moskowitz, M. A. (2005) · Neurology · doi:10.1212/wnl.64.10_suppl_2.s9 · Cited by 321
Neurogenic inflammation and its role in migraine
Ramachandran, R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0676-y · Cited by 310
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Charles, A., & Pozo-Rosich, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32504-8 · Cited by 304
Neuro-immune Interactions in the Tissues
Chu, C., Artis, D., & Chiu, I. M. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.017 · Cited by 301
Blocking CGRP in migraine patients – a review of pros and cons
On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS), Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltrán, E., Vigneri, S., Edvinsson, L., & Maassen Van Den Brink, A. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0807-1 · Cited by 298
The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache
OLESEN, J. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.003 · Cited by 296
Self-citationMarcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014) · Cephalalgia · doi:10.1177/0333102413500727 · Cited by 296
Self-citationAmin, F. M., Asghar, M. S., Hougaard, A., Hansen, A. E., Larsen, V. A., de Koning, P. J., Larsson, H. B., Olesen, J., & Ashina, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70067-x · Cited by 295
Self-citationDigre, K. B., & Brennan, K. C. (2012) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3182474548 · Cited by 293
Bigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Recent advances in understanding migraine mechanisms, molecules and therapeutics
Goadsby, P. J. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.005 · Cited by 279
Self-citationThe role of mast cells in migraine pathophysiology
Theoharides, T. C., Donelan, J., Kandere-Grzybowska, K., & Konstantinidou, A. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.11.006 · Cited by 264
Eftekhari, S., Salvatore, C. A., Johansson, S., Chen, T.-B., Zeng, Z., & Edvinsson, L. (2015) · Brain Research · doi:10.1016/j.brainres.2014.11.031 · Cited by 263
Hewitt, D. J., Aurora, S. K., Dodick, D. W., Goadsby, P. J., Ge, Y. (., Bachman, R., Taraborelli, D., Fan, X., Assaid, C., Lines, C., et al. (2011) · Cephalalgia · doi:10.1177/0333102411398399 · Cited by 263
Self-citationRandomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., Lines, C., Edvinsson, L., Goadsby, P. J., & Michelson, D. (2014) · Neurology · doi:10.1212/wnl.0000000000000771 · Cited by 262
Self-citationBigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Self-citationVasoactive Intestinal Peptide Causes Marked Cephalic Vasodilation, but does not Induce Migraine
Rahmann, A., Wienecke, T., Hansen, J., Fahrenkrug, J., Olesen, J., & Ashina, M. (2008) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01497.x · Cited by 257
Self-citationPathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies
Meng, I. D., Dodick, D., Ossipov, M. H., & Porreca, F. (2011) · Cephalalgia · doi:10.1177/0333102411402367 · Cited by 70
Kadmiel, M., Fritz-Six, K., Pacharne, S., Richards, G. O., Li, M., Skerry, T. M., & Caron, K. M. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0400 · Cited by 44
Brum, E. S., Landini, L., Souza Monteiro de Araújo, D., Marini, M., Geppetti, P., Nassini, R., De Logu, F., & Oliveira, S. M. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.01.040 · Cited by 8
Metadata
- Authors
- Olesen, J., Diener, H.-C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., Pollentier, S., & Lesko, L. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-11
- Volume
- 350
- Issue
- 11
- Pages
- 1104-1110
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048132386
- Cited by
- 1,189
- References
- 34
- FWCI
- 38.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.